No Data
Biocause Pharma's Insurance Unit Logs 31 Billion Yuan Insurance Premium Income in January-October Period
Express News | hubei biocause pharmaceutical: china best life insurance's original insurance premium income in January-October 2024 is approximately 31.386 billion yuan
Tianmao Group: Report for the third quarter of 2024
A-share insurance sector rises, hubei biocause pharmaceutical surges more than 7%.
On October 23rd, Biocause Pharmaceutical rose by over 7%, Kaisa Jiayun Technology Inc., Qitian Technology Group, Shenzhen Kingdom Sci-Tech, Jiangxi Tianli Technology, Inc., Ping An Insurance, Xin Hua Insurance and other companies followed the upward trend.
Tianmao Group: Tianmao Group\'s performance forecast for the first three quarters of 2024
hubei biocause pharmaceutical (000627.SZ) issued a profit warning, expecting a net loss of 0.315 billion yuan to 0.345 billion yuan in the first three quarters.
hubei biocause pharmaceutical (000627.SZ) released the performance forecast for the first three quarters of 2024, expecting the attributable net profit for the first three quarters to be above...
No Data
No Data